TY - JOUR
T1 - COVID-19 and thrombotic or thromboembolic disease
T2 - Implications for prevention, antithrombotic therapy, and follow-up
AU - Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function
AU - Bikdeli, Behnood
AU - Madhavan, Mahesh V
AU - Jimenez, David
AU - Chuich, Taylor
AU - Dreyfus, Isaac
AU - Driggin, Elissa
AU - Nigoghossian, Caroline Der
AU - Ageno, Walter
AU - Madjid, Mohammad
AU - Guo, Yutao
AU - Tang, Liang V
AU - Hu, Yu
AU - Giri, Jay
AU - Cushman, Mary
AU - Quéré, Isabelle
AU - Dimakakos, Evangelos P
AU - Gibson, C Michael
AU - Lippi, Giuseppe
AU - Favaloro, Emmanuel J
AU - Fareed, Jawed
AU - Caprini, Joseph A
AU - Tafur, Alfonso J
AU - Burton, John R
AU - Francese, Dominic P
AU - Wang, Elizabeth Y
AU - Falanga, Anna
AU - McLintock, Claire
AU - Hunt, Beverley J
AU - Spyropoulos, Alex C
AU - Barnes, Geoffrey D
AU - Eikelboom, John W
AU - Weinberg, Ido
AU - Schulman, Sam
AU - Carrier, Marc
AU - Piazza, Gregory
AU - Beckman, Joshua A
AU - Steg, P Gabriel
AU - Stone, Gregg W
AU - Rosenkranz, Stephan
AU - Goldhaber, Samuel Z
AU - Parikh, Sahil A
AU - Monreal, Manuel
AU - Krumholz, Harlan M
AU - Konstantinides, Stavros V
AU - Weitz, Jeffrey I
AU - Lip, Gregory Y H
N1 - Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
PY - 2020/6/16
Y1 - 2020/6/16
N2 - Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.
AB - Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who have thrombotic disease. Herein, the authors review the current understanding of the pathogenesis, epidemiology, management, and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, of those with pre-existing thrombotic disease who develop COVID-19, or those who need prevention or care for their thrombotic disease during the COVID-19 pandemic.
KW - Anticoagulants/pharmacology
KW - Betacoronavirus/isolation & purification
KW - COVID-19
KW - Coronavirus Infections/blood
KW - Fibrinolytic Agents/pharmacology
KW - Humans
KW - Pandemics
KW - Platelet Aggregation Inhibitors/pharmacology
KW - Pneumonia, Viral/blood
KW - SARS-CoV-2
KW - Thromboembolism/drug therapy
KW - Treatment Outcome
UR - https://www.elsevier.com/open-access/open-archive
U2 - 10.1016/j.jacc.2020.04.031
DO - 10.1016/j.jacc.2020.04.031
M3 - Review article
C2 - 32311448
SN - 0735-1097
VL - 75
SP - 2950
EP - 2973
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 23
ER -